JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Cliff Donald Blessing, the Executive Vice President and Chief Development Officer at Addus HomeCare Corp (NASDAQ:ADUS), a $1.73 billion market cap healthcare services provider, recently made a notable stock transaction amid a challenging period for the stock, which has declined about 15% in the past week. On February 25, Blessing sold 191 shares of common stock, with a total transaction value of $19,063. The shares were sold at a weighted average price of $99.81, with individual sale prices ranging from $99.79 to $99.87. This transaction was executed under a previously established 10b5-1 plan to satisfy tax obligations related to the vesting of restricted stock awards. Following the sale, Blessing retains ownership of 10,579 shares of Addus HomeCare stock. According to InvestingPro analysis, the company currently trades at a P/E ratio of 22.8x and shows signs of being slightly undervalued based on its Fair Value assessment. For deeper insights and access to 10+ additional ProTips about ADUS, including detailed valuation metrics, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Addus HomeCare Corporation reported its fourth-quarter 2024 earnings, which surpassed analyst expectations with an earnings per share (EPS) of $1.38 against a forecast of $1.35. Revenue also exceeded projections, reaching $297.1 million compared to the anticipated $284.28 million. Despite these positive results, the company’s stock experienced a decline, reflecting investor concerns over broader market conditions and potential changes in Medicaid policy. KeyBanc Capital Markets maintained an Overweight rating on Addus HomeCare, highlighting strong growth in the Personal Care segment and a successful Gentiva acquisition. The firm noted the company’s resilience against potential Medicaid changes, although market uncertainty has impacted stock valuation. Meanwhile, Stephens adjusted its price target for Addus HomeCare to $142.00 from $153.00, maintaining an Overweight rating, while emphasizing the company’s strong revenue growth strategy and M&A pipeline. Raymond (NSE:RYMD) James also lowered its price target to $120 from $140, citing concerns over Medicaid cuts but maintaining an Outperform rating due to the company’s solid execution and cash flow generation. These developments reflect a complex landscape for Addus HomeCare, balancing strong financial performance with external policy uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.